Platinum-based chemotherapy in metastatic breast cancer: current status

This publication has 180 references indexed in Scilit:

• Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene
  European Journal Of Cancer, 2001
• Treatment of Breast Cancer
  New England Journal of Medicine, 1998
• Phase II study of 4-epirubicin, etoposide and cisplatin as neoadjuvant chemotherapy in locally advanced breast cancer
  European Journal Of Cancer, 1994
• Taxol and Cisplatin Inhibit Proliferation of T47D Human Breast Cancer Cells
  Biochemical and Biophysical Research Communications, 1994
• First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer
  European Journal Of Cancer, 1993
• Negative phase II study with carboplatin and 5-fluorouracil in advanced breast cancer
  European Journal Of Cancer, 1992
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990
• Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes
  Chemico-Biological Interactions, 1989
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987
• Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting
  New England Journal of Medicine, 1981